The current situation and challenges of the development of DNA coding compound library technology.

On October 19, 2018, Landmark Chengdu was co-sponsored by Chengdu Pilot Pharmaceutical Development Co., Ltd., Pfizer Asia Innovation Center, Mercadon Research and Development (China), Johnson and Johnson Asia-Pacific Innovation Center, GlaxoSmithKline and Shenzhen Microcore Biotech Co., Ltd.
Forum upholds the theme of "Innovation, Pragmatism and Cooperation" and more than a thousand people gathered in Lucheng to share the feast.
Conference invited 68 heavyweight experts and scholars from home and abroad, such as government regulators, academia, industry, business and venture capital, to give keynote speeches, focusing on the analysis and policy analysis of the biopharmaceutical market at home and abroad, studying new trends in the intelligent medical industry, discussing new targets and new technologies for new drug research and development, and sharing many examples of first-line new drug research and development at home and abroad.
is worth noting that, as a global professional summit focusing on DEL, the 8th International Summit Forum on DNA Coding CompoundS Library Technology moved to China for the first time, the past seven in Boston, USA and Zurich, Switzerland, and will be held in the United States, Switzerland, Chengdu, China, on a rotating basis from this year. During the
, Dr. Barry Morgan, chief scientist of DNA coding compound sourcing technology, lead chief scientist of Chengdu, Deputy Director of Science at the European Department of Chemistry in Mersadon, Inventor of Viagra Van Aike, Dr. Kenneth E. E. , Manager of GlaxoSmithKline's Scientific Computing Research and Development Platform, Professor of Chemistry and Applied Biosciences at the Swiss Federal Institute of Technology and Co-Founder of the International Forum on DNA Coding Compounds, was interviewed by Dr.
(left) Dr. Barry Morgan, Dr. Nick Terrett, Dr. Kenneth E Lind, Professor Dario Neri (right) Reporter: What has been the way in the DNA coding compound library? Dr. Nick Terrett (Deputy Director of Science, European Chemistry, Viagra Van Aike) 20 years ago, combined chemistry was put into industrial use with the aim of synthesizing large, diverse compounds in a short period of time and discovering pharmaceutical molecules.
the 1990s, many technologies were invented in academia and industry to synthesize high-quality compound banks.
in many combination chemistry methods, DNA coding compound library technology has been paid attention to and widely used in industry.
many head compounds have been discovered from DNA coding compound technology, optimized into lead compounds, and several have entered the clinical phase.
this is a testament to the impact of DNA coding compound technology.
reporter: You came to Chengdu for a meeting, the main share of what kind of cutting-edge information? Dr. Barry Morgan (Lead Inventor of DNA Coding CompoundLibrary Technology, Lead Chief Scientist, Chengdu): I think there are two important frontiers: first, we see the screening of compounds in the DNA coding compound library into clinical studies, which will change the lives of patients;
Dr. Kenneth E Lind (Manager, GlaxoSmithKline Scientific Computing Research and Development Platform): I agree with Barry that I was impressed by the new chemistry and application in the DNA coding compound library.
on the other hand, we can learn about the screening methods for new DNA-coding compound banks.
Reporter: The forum was held in Chengdu for the first time, what is the difference between the past participation? Professor Dario Neri (Professor of Chemistry and Applied Biological Sciences, Swiss Federal Institute of Technology and Co-Founder of Philogen, Founder of the International Summit on DNA Coding CompoundS Library Technology): This is the best of all, the Organizing Committee has organized this meeting very well, with very good presentation topics, and very new scientific advances.
Reporter: What are the biggest challenges in building a DNA-coded compound library? Dario Neri: The quantity and quality of THE DNA-coded compound library.
Nick Terrett: Building a library of structurally diverse, drug-like DNA-coding compounds, and the discovery of drug-like molecules through the screening of the compound library, will be a challenge for dna coding compound banks. kenneth E Lind,
: It is important to find high-quality molecules through the DNA coding compound library;
Reporter: What do you think of the DNA Coding Compound Systunto Summit in Chengdu? Nick Terrett: This is my second visit to Chengdu.
especially the development of the biological city, I was very shocked.
Reporter: Chengdu this year to join Zurich, Boston, the three cities will take turns to hold this summit forum, what do you expect? Dario Neri: Chengdu is an important and peer-to-peer partner.
I think the mechanism of this rotation will be very good and should continue.
From the 2nd International Summit on Frontiers and Practices in Innovative Drug Discovery, I began to attend, and today it is the third, the trend is that the number of people at the summit is increasing and technology is improving.
Barry Morgan: If we combine short-term and long-term benefits, I think these academic summits have far-reaching implications for the industry and for Chengdu.
thanks to Dr. Barry Morgan, Dr. Nick Terrett, Dr. Kenneth E Lind and Professor Dario Neri for their interviews.
Source: Pharmaceutical Intelligence Network.